Viatris closes €1.95B divestiture of over-the-counter business to Cooper Consumer Health

Viatris Inc

Received €1.85B cash at closing (subject to adjustments) and up to €100M contingent additional consideration.
Buyer paid €25M advance toward transition services fees at closing.
€120M of closing consideration retained by buyer for pending sale of select geography portions.
Transaction closed on July 3, 2024, as previously announced in January 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.